Skip to main content
SpringerLink
Log in
Book cover

Laryngopharyngeal and Gastroesophageal Reflux pp 285–323Cite as

Proton Pump Inhibitor Controversies

  • Chapter
  • First Online:

  • 540 Accesses

Abstract

This chapter is an overview of the proton pump inhibitors. Mechanism of action, dosing, and success evaluation is followed by a detailed look at the potential risks of this medication. Recent studies have suggested potential links with the use of this medication and other chronic diseases. This chapter reviews these studies and the statistical methods used to draw conclusions.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Strand DS, Kim D, et al. 25 years of proton pump inhibitors: a comprehensive review. Gut and Liver. 2017;11(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  2. Coleman HG, et al. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154:390–405.

    Article  PubMed  Google Scholar 

  3. Patel M, Lee AD, Clemmons NS, et al. National update on measles cases and outbreaks — United States, January 1–October 1, 2019. MMWR Morb Mortal Wkly Rep. ePub: 4 October 2019. https://doi.org/10.15585/mmwr.mm6840e2.

  4. Schubert ML. Proton pump inhibitors: placing putative adverse effects in proper perspective. Curr Opin Gastroenterol. 2019;35:509–16.

    Article  CAS  PubMed  Google Scholar 

  5. Vaezi MF, et al. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48.

    Article  CAS  PubMed  Google Scholar 

  6. Bester JC. Measles and measles vaccination: a review. JAMA Pediatr. 2016;170(12):1209–15.

    Article  PubMed  Google Scholar 

  7. Gawron AJ, French DD, et al. Economic evaluations of gastroesophageal reflux disease medical management: a systematic review. PharmacoEconomics. 2014 Aug;32(8):745–58.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health. 2009;12:34–9.

    Article  PubMed  Google Scholar 

  9. Kleiman DA, Sporn MJ, et al. Early referral for 24-hour esophageal pH monitoring may prevent unnecessary treatment with acid-reducing medications. Surg Endosc. 2013 Apr;27(4):1302–9.

    Article  PubMed  Google Scholar 

  10. Carroll TL, Werner A, et al. Rethinking the laryngopharyngeal reflux treatment algorithm: evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease. Laryngoscope. 2017 Oct;127(Suppl 6):S1–S13.

    Article  CAS  PubMed  Google Scholar 

  11. Funk LM, Zhang JY, et al. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease. Surgery. 2015 Jan;157(1):126–36.

    Article  PubMed  Google Scholar 

  12. Faria R, Bojke L, et al. Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. Br J Surg. 2013 Aug;100(9):1205–13.

    Article  CAS  PubMed  Google Scholar 

  13. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–7.

    Article  CAS  PubMed  Google Scholar 

  14. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and helicobacter pylori status. Gastroenterology. 1999;116:239–47.

    Article  CAS  PubMed  Google Scholar 

  16. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric secretion. Aliment Pharmacol Ther. 2005;21:149–54.

    Article  CAS  PubMed  Google Scholar 

  17. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.

    Article  CAS  PubMed  Google Scholar 

  18. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019;10:1–13.

    Article  Google Scholar 

  19. Laine L, Nagar A. Long-term PPI use: balancing potential harms and documented benefits. Am J Gastroenterol. 2016;111:913–5.

    Article  CAS  PubMed  Google Scholar 

  20. Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med. 2013;28:223–30.

    Article  PubMed  Google Scholar 

  21. Otani IM, Banerji A. Immediate and delayed hypersensitivity reactions to proton pump inhibitors: evaluation and management. Curr Allergy Asthma Rep. 2016;16:17.

    Article  PubMed  CAS  Google Scholar 

  22. Food and Drug Administration 2009. FDA Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm.

  23. Eusebi LH, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32:1295–302.

    Article  PubMed  Google Scholar 

  24. Hvid-Jensen F, et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39(9):984–91.

    Article  CAS  PubMed  Google Scholar 

  25. Brusselaers N, et al. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidimiol. 2018;53:172–7.

    Article  Google Scholar 

  26. Krishnamoorthi R, et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc. 2016;84(1):40–6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.

  28. SEER Cancer Stat Facts: Esophageal Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/esoph.html. Accessed 9 Aug 2019.

  29. Kane SP. Omeprazole, ClinCalc DrugStats Database, Version 19.1. ClinCalc: https://clincalc.com/DrugStats/Drugs/Omeprazole. Updated November 24, 2018. Accessed 9 Aug 2019.

  30. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37.

    Article  PubMed  Google Scholar 

  31. Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One. 2017;12:e0169691.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Maret-Ouda J, Konings P, Lagergren J, et al. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg. 2016;263:251–7.

    Article  PubMed  Google Scholar 

  33. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19:2560–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Garcia-Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55:1538–44.

    Article  CAS  PubMed  Google Scholar 

  36. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:CD010623.

    Google Scholar 

  37. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74.

    Article  CAS  PubMed  Google Scholar 

  38. Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:73–82.

    Article  CAS  PubMed  Google Scholar 

  39. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748–54.

    Article  CAS  PubMed  Google Scholar 

  40. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case–control study. Gastroenterology. 2007;133:755–60.

    Article  PubMed  Google Scholar 

  41. van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966–73.

    Article  PubMed  Google Scholar 

  42. Schnoll-Sussman F, Katz PO. Clinical implications of emerging data on the safety of proton pump inhibitors. Curr Treat Options Gastro. 2017;15:1–9.

    Article  Google Scholar 

  43. Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes. 2015;8:47–55.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172–4.

    Article  PubMed  Google Scholar 

  46. Patil AS, Singh AD, Mahajan UB, et al. Protective effect of omeprazole and lansoprazole on b-receptor stimulated myocardial infarction in Wistar rats. Mol Cell Biochem. 2019;456:105–13.

    Article  CAS  PubMed  Google Scholar 

  47. Yang X, Yue R, Zhang J, et al. Gastrin protects against myocardial ischemia/ reperfusion injury via activation of RISK (reperfusion injury salvage kinase) and SAFE (survivor activating factor enhancement) pathways. J Am Heart Assoc. 2018;7(14):e005171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.

    Article  CAS  PubMed  Google Scholar 

  49. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152:337–45.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Batchelor R, Kumar R, Gilmartin-Thomas JFM, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48:780–96.

    Article  CAS  PubMed  Google Scholar 

  51. Landi SN, Sandler RS, Pate V, Lund JL. No increase in risk of myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2 receptor antagonists. Gastroenterology. 2018;154:861–73.

    Article  PubMed  Google Scholar 

  52. Sehested TSG, et al. Long-term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283:268–81.

    Article  CAS  PubMed  Google Scholar 

  53. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Xie Y, et al. Estimates of all-cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–28.

    Article  PubMed  Google Scholar 

  56. Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:41–416.

    Google Scholar 

  57. Kuller LH. Do proton pump inhibitors increase the risk of dementia? JAMA Neurol. 2016;73:379–81.

    Article  PubMed  Google Scholar 

  58. Goldstein FC, et al. Proton pump inhibitors and risk for mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65(9):1969–74.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112:1802–8.

    Article  CAS  PubMed  Google Scholar 

  60. Lockhead P, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971–9.

    Article  CAS  Google Scholar 

  61. Wod M, et al. Lack of association between proton pump inhibitor use and cognitive decline. Clin Gastroenterol Hepatol. 2018;16:681–9.

    Article  CAS  PubMed  Google Scholar 

  62. Li M, et al. Proton pump inhibitor use and risk of dementia: systematic review and meta-analysis. Medicine. 2019;98:7.

    Google Scholar 

  63. Hussain S, et al. No association between proton pump inhibitor use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol. 2020;35(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  64. Song YQ, et al. Proton pump inhibitor use does not increase dementia and Alzheimer’s disease risk: an updated meta-analysis of published studies involving 642,305 patients. PLoS One. 2019;14:7.

    Google Scholar 

  65. Park SK, Baek YH, Pratt N, et al. The uncertainty of the association between proton pump inhibitor use and the risk of dementia: prescription sequence symmetry analysis using a Korean healthcare database between 2002 and 2013. Drug Saf. 2018;41:615–24.

    Article  CAS  PubMed  Google Scholar 

  66. Park SK, et al. Beyond uncertainty: negative findings for the association between the use of proton pump inhibitors and risk of dementia. J Gastroenterol Hepatol. 2019;. epub ahead of print

    Google Scholar 

  67. Booker A, Jacob LE, Rapp M, et al. Risk factors for dementia diagnosis in German primary care practices. Value Health J Int Soc Pharm Outcomes Res. 2015;18:1–7.

    Google Scholar 

  68. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump. Accessed 9 Aug 2019.

  69. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–47.

    Article  CAS  PubMed  Google Scholar 

  70. Poly TN, Islam MM, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103–14.

    Article  CAS  PubMed  Google Scholar 

  71. Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141–51.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Liu J, Li X, Fan L, et al. Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci. 2019;218:213–23.

    Article  CAS  PubMed  Google Scholar 

  73. Lin SM, Yang SH, Liang CC, Huang HK. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporosis Int. 2018;29:153–62.

    Article  CAS  Google Scholar 

  74. Torvinen-Kiiskinen S, Tolppanen AM, Koonen M, et al. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer’s disease - a nested case-control study. Aliment Pharmacol Ther. 2018;47:1135–42.

    Article  CAS  PubMed  Google Scholar 

  75. Fedida B, Schermann H, Ankory R, et al. Fracture risk of young adults receiving proton pump inhibitors and H2-receptor antagonists. Int J Clin Pract. 2019;4:13339.

    Article  CAS  Google Scholar 

  76. Lai SW, Lin CH, Liao KF. Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan. Eur Geriatr Med. 2018;9:169–74.

    Article  PubMed  Google Scholar 

  77. Lai SW, Lin CL, Uao KF. Proton pump inhibitors therapy and the risk of major osteoporotic nonhip fractures in older adults in Taiwan. Eur J Gastroenterol Hepatol. 2019;31:272–3.

    Article  PubMed  Google Scholar 

  78. Harding BN, et al. Proton pump inhibitor use and the risk of fractures among an older adult cohort. Pharmacoepidemiol Drug Saf. 2018;27(6):596–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Levy MD, Bhattacharya B. Sporadic fundic gland polyps with low-grade dysplasia: a large case series evaluating pathologic and immunohistochemical findings and clinical behavior. Am J Clin Pathol. 2015;144(4):592–600.

    Article  CAS  PubMed  Google Scholar 

  80. Cheesman AR, Greenwald DA, Shah SC. Current management of benign epithelial gastric polyps. Curr Treat Options Gastro. 2017;15:676.

    Article  Google Scholar 

  81. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10

    Google Scholar 

  82. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Zirk-Sadowski J, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 2018;66(7):1332–8.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Filion KB, Chateau D, Targownik LE, et al. CNODES investigators. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.

    Article  CAS  PubMed  Google Scholar 

  85. Othman F, et al. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97:797–802.

    Article  CAS  PubMed  Google Scholar 

  87. Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42:607–13.

    Article  CAS  PubMed  Google Scholar 

  88. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74.

    Article  PubMed  CAS  Google Scholar 

  89. Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med. 2018;44(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  90. Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-clostridium-difficile-associated-diarrhea-can-be-associated-stomach. Accessed 9 Aug 2019.

  91. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7:e50836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.

    Article  PubMed  Google Scholar 

  93. Arriola V, Tischendorf J, Musuuza J, et al. Assessing the risk of hospital-acquired Clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016;37(12):1408–17.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225–33.

    Article  CAS  PubMed  Google Scholar 

  95. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.

    Article  CAS  PubMed  Google Scholar 

  96. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Bonderup OK, Nielsen GL, Dall M, et al. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther. 2018;48:618–25.

    Article  CAS  PubMed  Google Scholar 

  98. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;

    Google Scholar 

  99. Faisal K, Khan MA, Miklos MZ, et al. The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease. J Clin Gastroenterol. 2018;52:468–76.

    Article  CAS  Google Scholar 

  100. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3:E166–71.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case–control study. BMC Nephrol. 2013;14:150.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case– control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86:837–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Nochaiwong S, Ruengom C, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–42.

    Article  CAS  PubMed  Google Scholar 

  104. Lee J, Mark RG, Celi LA, et al. Proton pump inhibitors are not associated with acute kidney injury in critical illness. J Clin Pharmacol. 2016;56:1500–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21:1155–72.

    Article  CAS  PubMed  Google Scholar 

  106. Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J Pharm Policy Pract. 2019;12:6.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Wijarnpreecha K, Thongprayoon C, et al. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017;62:2821–7.

    Article  CAS  PubMed  Google Scholar 

  108. Lazarus B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2011;76:238–46.

    Google Scholar 

  110. Arora P, Golzy M, Gupta A, Ranjan R, Carter R, Lohr J. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. J Am Soc Nephrol. 2015;26:219A.

    Google Scholar 

  111. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;

    Google Scholar 

  112. Klatte DCF, Gasparini A, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.

    Article  CAS  PubMed  Google Scholar 

  113. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–42.

    Article  CAS  PubMed  Google Scholar 

  114. den Elzen WP, Groeneveld Y, de Ruijter Wet al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491–497.

    Google Scholar 

  115. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422–8.

    Article  PubMed  Google Scholar 

  116. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.

    Article  PubMed  CAS  Google Scholar 

  117. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364–8.

    Article  CAS  PubMed  Google Scholar 

  118. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12:83–98.

    Article  CAS  PubMed  Google Scholar 

  121. Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56:2349–53.

    Article  CAS  PubMed  Google Scholar 

  123. Food and Drug Administration. FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Silver Spring, MD: Available at: http://www.fda.gov/drugs/drugsafety/ucm245011.htmUS Food and Drug Administration, 2011. Accessed 9 Aug 2019.

  124. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237–41.

    Article  CAS  PubMed  Google Scholar 

  125. Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014;9(11):e112558.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015;66(5):775–82.

    Article  CAS  PubMed  Google Scholar 

  127. Mikolasevic I, Milic S, Stimac D, et al. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis? Eur J Intern Med. 2016;30:99–103.

    Article  CAS  PubMed  Google Scholar 

  128. Liu J, Li X, Fan L, et al. Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci. 2019;218:213–23.

    Article  CAS  PubMed  Google Scholar 

  129. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Targownik LE, Goertzen AL, Luo Y, et al. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  131. Arj A, Razavi ZM, Yavari M, et al. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016;19(9):864–8.

    Article  CAS  PubMed  Google Scholar 

  132. Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2015;30:232–9.

    Article  CAS  PubMed  Google Scholar 

  133. Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31:206–11.

    Article  CAS  PubMed  Google Scholar 

  135. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896–904.

    Article  CAS  PubMed  Google Scholar 

  136. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170:765–71.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Hansen KE, Nieves JW, Nudurupati S, et al. Dexlansopraole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019;156:926–34.

    Article  CAS  PubMed  Google Scholar 

  139. Black DM, Rosen CJ. Clinical practice: postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62.

    Article  CAS  PubMed  Google Scholar 

  140. Nguyen LH, Lochhead P, Joshi AD, et al. No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indications. Gastroenterology. 2018;154:1290–7.

    Article  CAS  PubMed  Google Scholar 

  141. Wang YF, Chen YT, Luo JC, et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112:1084–93.

    Article  CAS  PubMed  Google Scholar 

  142. Czwornog JL, Austin GL. Association of proton pump inhibitor (PPI) use with energy intake, physical activity, and weight gain. Nutrients. 2015;7:8592–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Moayyedi P, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–91.

    Article  CAS  PubMed  Google Scholar 

  144. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79–94.

    Article  CAS  PubMed  Google Scholar 

  145. Yoon SL, Grundmann O, Smith KF, Mason SR. Dietary supplement and complementary and alternative medicine use are highly prevalent in patients with gastrointestinal disorders: results from an online survey. J Diet Suppl. 2018;29:1–14.

    Google Scholar 

  146. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015;5(11):CD003243.

    Google Scholar 

  147. Brisbois S, Merati A, et al. Proton pump inhibitors: review of reported risks and controversies. Laryngoscope investigative otolaryngology 2018. Open Access.

    Google Scholar 

  148. Nehra AK, et al. Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc. 2018;93(2):240–6.

    Article  CAS  PubMed  Google Scholar 

  149. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–15.

    Article  CAS  PubMed  Google Scholar 

  150. Jaworek AJ, Sataloff RT. Gluten sensitivity. J Singing. 2019;75(3):303–8.

    Google Scholar 

Download references

Important Disclaimer

GERD and LPR presentation and management have many distinctions. Most of the studies included in this chapter were for patients with GERD. Arguably, this makes generalizability more difficult (different study populations, overlapping symptomatology, and differential diagnosis). It is established that the most fundamental (albeit oversimplified) threshold for adequate LPR control is ≤1 pharyngeal reflux event daily, and for GERD <48 esophageal events daily (not to mention acid exposure times, weakly acid and nonacid reflux, mucosal changes, and patients’ symptoms). This observation opens the door for even more needed research, not only to clarify association vs causation for the risks discussed but also to understand better the impact of PPI use on patients with LPR.

Author information

Authors and Affiliations

  1. Drexel University College of Medicine, Department of Otolaryngology – Head and Neck Surgery, Philadelphia, PA, USA

    Aaron J. Jaworek

  2. Temple University Lewis Katz School of Medicine, Department of Otolaryngology – Head and Neck Surgery, Philadelphia, PA, USA

    Aaron J. Jaworek

Authors
  1. Aaron J. Jaworek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ENT and Allergy Associates, LLP; Voice and Swallow Division, Tarrytown, NY, USA

    Craig H. Zalvan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jaworek, A.J. (2020). Proton Pump Inhibitor Controversies. In: Zalvan, C.H. (eds) Laryngopharyngeal and Gastroesophageal Reflux. Springer, Cham. https://doi.org/10.1007/978-3-030-48890-1_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48890-1_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48889-5

  • Online ISBN: 978-3-030-48890-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation